GK730

GK730 is a potent and selective SARS-CoV-2 main protease inhibitor with an IC50 of 5.75 nM. GK730 does not inhibit cathepsin B, while exhibits weak inhibition of cathepsin L (IC50 = 11 μM) . GK730 can simultaneously block the replication of the virus and the entry pathways for variants such as Omicron into cells. GK730 demonstrates an EC50 value of 5.70 μM against a wild-type SARS-CoV-2 strain in Vero E6 cells and CC50 value greater than 100 μM. GK730 can be used for the research of COVID-19[1].

Product Specifications

UNSPSC

12352005

Target

SARS-CoV

Related Pathways

Anti-infection

Field of Research

Infection

Smiles

O=C(N[C@@H](C(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](C[C@@H]1CCNC1=O)C(C2=NC(C(OC)=O)=CS2)=O)=O)=O)OCC3=CC=CC=C3

Molecular Formula

C31H41N5O8S

Molecular Weight

643.75

References & Citations

[1]Theodoropoulou MA, et al. Thiazolyl 4-carboxylate ketone as a new warhead for a highly potent SARS-CoV-2 main protease inhibitor. Eur J Med Chem. 2026 Feb 5;303:118436.